📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-21 18:48
341 analysed today
FollowTelegram
341
Today
150,292
All-time analysed
43,051
Positive
6,683
Negative
91,826
Neutral
8,664
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
22 announcements match the current filters (relevance ≥ 5).
PI Industries Receives Registration for Indigenously Discovered Insecticide 'Pioxaniliprole'
PI Industries announced that it has received regulatory registration under section 9(3) of the Insecticides Act, 1968, for 'Pioxaniliprole' (branded as 'Pioxazon') for TIM and FIM categories. The approval stems from the 476th registration committee meeting held on September 10, 2026, and officially published on September 21, 2026. Described as India's first indigenously discovered and developed insecticide molecule, the product was created over a decade of R&D and will launch in the domestic market soon. This supports PI's broader strategy to expand its domestic branded formulations portfolio, which currently operates alongside its TTM revenue base of Rs 6,607 Cr.
Confidence: HIGH
What changedPI Industries received formal registration approval to manufacture and market its first indigenously discovered insecticide molecule, Pioxaniliprole ('Pioxazon'), in India.
Why it mattersMarks a major shift from contract research/manufacturing to commercializing self-discovered proprietary IP, potentially bolstering domestic market share and proprietary formulation margins.
Meeting reference: 476th registration committee meetingMeeting date: September 10, 2026Registration notification date: September 21, 2026TTM Revenue context: Rs 6,607 Cr
📅 Short termPositive sentiment driver as the regulatory hurdle is cleared; commercial revenue contribution will depend on distribution ramp-up and pricing details upon launch.
📈 Long termValidates PI's R&D capabilities in discovering novel chemical entities, supporting its strategic transition toward proprietary IP and margin-accretive branded formulations.
⚠ Risk flags
- Market adoption and competitive pricing dynamics against established alternatives
- Exposure to domestic agrochemical demand fluctuations and monsoon performance
Key Highlights
Granted regulatory registration for 'Pioxaniliprole' under section 9(3) of the Insecticides Act, 1968, for TIM and FIM categories
Product branded as 'Pioxazon', developed over a decade of in-house research
Registration approved pursuant to the 476th registration committee meeting held on September 10, 2026
Targets the domestic crop protection market, with commercial launch planned soon
👀 What to Watch
Track the commercial rollout timeline of Pioxazon in upcoming quarters and management commentary on domestic market revenue potential and gross margin contributions.
PI Industries Q1 FY27: PAT Drops 39% to ₹244 Cr Amid Export Headwinds
PI Industries reported a weak Q1 FY27 with consolidated revenue declining 10% YoY to ₹17,023 Mn, primarily due to a 12% drop in Agchem exports. Profitability was significantly impacted as EBITDA fell 29% to ₹3,693 Mn and PAT dropped 39% to ₹2,442 Mn, driven by pricing pressures and higher input costs. Despite global disruptions, domestic volumes grew 12% and the biologicals segment surged over 50% YoY. The company remains financially robust with a net cash surplus of ₹37,939 Mn and continued its investment strategy with a Q1 capex of ₹2,685 Mn.
Confidence: HIGH
What changedThe company transitioned from high growth to a cyclical downturn in its core export business, leading to significant margin compression.
Why it mattersAs a leading CSM player, the 12% drop in PI's exports signals persistent global inventory issues and pricing pressure, testing the company's ability to pivot toward its newer Pharma and Biological segments.
Revenue (Q1 FY27): ₹17,023 MnPAT (Q1 FY27): ₹2,442 MnEBITDA Margin: 22%Net Cash Balance: ₹37,939 MnQ1 Capex vs TTM Revenue: ~4.06%
📅 Short termThe stock may face downward pressure in the near term due to the significant miss in PAT and EBITDA margins compared to the previous year.
📈 Long termThe structural shift toward Biologicals and Pharma CDMO remains intact, but the recovery of the core Agchem export business is critical for returning to historical growth rates.
⚠ Risk flags
- Global agrochemical demand softness
- Pricing pressure from Chinese supply deluge
- Order phasing delays in Pharma (PIHS) segment
- Input cost inflation due to geopolitical issues
Key Highlights
Consolidated Revenue declined 10% YoY to ₹17,023 Mn, with Agchem exports falling 12%.
Net Profit (PAT) saw a sharp 39% YoY contraction to ₹2,442 Mn.
Domestic Biologicals segment showed strong momentum with 50%+ YoY growth.
Net Working Capital improved by 19 days, reducing to 120 days as of June 2026.
Total Capex for the quarter stood at ₹2,685 Mn, focusing on manufacturing and R&D.
👀 What to Watch
Investors should monitor the recovery timeline for global agrochemical demand and the stabilization of export margins, while tracking the execution of the 20+ products currently in the innovation pipeline.
PI Industries Q1 Revenue Declines 10.4% to ₹1,702 Cr; Forms CSR Subsidiary
PI Industries reported a consolidated revenue of ₹1,702.3 Cr for Q1 FY27, marking a 10.4% decline from ₹1,900.5 Cr in Q1 FY26. Standalone net profit for the quarter fell significantly to ₹341.5 Cr compared to ₹464.3 Cr in the same period last year. The company also announced the incorporation of 'PI Foundation', a wholly-owned Section 8 subsidiary dedicated to CSR activities with a nominal initial capital of ₹1 lakh. These results reflect ongoing headwinds in the agrochemical sector, despite the company's robust ₹13,000 Cr (USD 1.4 billion) order book.
Confidence: HIGH
What changedPI Industries reported a year-on-year decline in both revenue and profitability for the June 2026 quarter and formalized its CSR operations into a separate subsidiary.
Why it mattersThe revenue and profit contraction indicates that even high-quality CSM players like PI Industries are not immune to the current global agrochemical slowdown and pricing pressures. The formation of the Section 8 company is a routine administrative step for CSR compliance.
Q1 Consolidated Revenue: ₹1,702.3 CrRevenue Growth (YoY): -10.4%Standalone EPS (Q1): ₹22.50Q1 Revenue vs TTM Revenue: 25.7%PI Foundation Initial Capital: ₹1,00,000
📅 Short termThe stock is likely to face downward pressure in the short term as the market reacts to the double-digit revenue decline and lower-than-expected profitability.
📈 Long termThe long-term outlook depends on the company's ability to diversify into Pharma CDMO and Biologicals and the successful commercialization of its molecule pipeline to offset agrochemical volatility.
⚠ Risk flags
- Global agrochemical industry slowdown
- Pricing pressure from Chinese exports
- Execution risk in the new Pharma CDMO segment
Key Highlights
Consolidated revenue for Q1 FY27 decreased by 10.4% YoY to ₹1,702.3 Cr.
Standalone Net Profit for the quarter dropped to ₹341.5 Cr from ₹464.3 Cr YoY.
Standalone EPS for the quarter stood at ₹22.50, down from ₹30.61 in Q1 FY26.
Board approved the incorporation of 'PI Foundation' as a 100% subsidiary with ₹1,00,000 initial capital.
Standalone Profit Before Tax (PBT) for the quarter was ₹437.0 Cr vs ₹581.5 Cr in the previous year's quarter.
👀 What to Watch
Investors should monitor management commentary regarding the 'supply deluge from China' and its impact on pricing realizations. Key to recovery will be the execution of the USD 1.4 billion order book and the ramp-up of the newly acquired pharma and biological entities.
PI Industries Q1 FY27: Net Profit drops 39% YoY to ₹244 Cr; Revenue down 10% to ₹1,702 Cr
PI Industries reported a weak start to FY27, with consolidated revenue declining 10.4% YoY to ₹1,702.3 Cr. Net profit saw a sharper contraction, falling 38.9% YoY to ₹244.2 Cr, compared to ₹400.0 Cr in the year-ago period. While revenue showed a sequential recovery of 8.7% from Q4 FY26, margins remained under pressure with Profit Before Tax (before exceptional items) at 18.9% of revenue. The board also approved the incorporation of 'PI Foundation' for CSR activities.
Confidence: HIGH
What changedPI Industries reported its Q1 FY27 financial results, marking a significant year-on-year decline in both revenue and profitability.
Why it mattersThe results indicate a slowdown in the core agrochemical business and margin compression, which contrasts with the company's historical high-growth trajectory and IP-backed pricing power.
Consolidated Revenue (Q1): ₹1,702.3 CrConsolidated Net Profit (Q1): ₹244.2 CrYoY Revenue Growth: -10.4%YoY Net Profit Growth: -38.9%Q1 Revenue vs TTM Revenue: 25.7%
📅 Short termThe stock is likely to face negative sentiment in the short term due to the substantial earnings miss and margin contraction compared to the previous year.
📈 Long termStructural growth depends on the diversification into Pharma CDMO and biologicals; however, the current cyclical downturn in agrochemicals is weighing on performance.
⚠ Risk flags
- Significant margin contraction
- Rising employee costs
- Pricing pressure from global supply deluges
Key Highlights
Consolidated Revenue from operations fell 10.4% YoY to ₹1,702.3 Cr from ₹1,900.5 Cr.
Consolidated Net Profit declined 38.9% YoY to ₹244.2 Cr from ₹400.0 Cr in June 2025.
Employee benefit expenses increased 12.3% YoY to ₹260.8 Cr, impacting operating margins.
Consolidated EPS dropped significantly to ₹16.10 from ₹26.37 in the same quarter last year.
Finance costs doubled YoY to ₹7.9 Cr, though debt remains low relative to net worth.
👀 What to Watch
Investors should monitor management commentary regarding the $1.4 billion order book execution and the impact of Chinese supply deluges on pricing. The key to recovery lies in the successful ramp-up of the newly acquired pharma and biological segments.
Rs 10 Final Dividend: PI Industries Sets August 7, 2026, as Record Date
PI Industries has announced August 7, 2026, as the record date for a final dividend of Rs 10 per equity share for the financial year 2025-26. The dividend is subject to shareholder approval at the upcoming 79th Annual General Meeting (AGM) scheduled for August 14, 2026. Based on the current market price of Rs 2,631.8, this represents a dividend yield of approximately 0.38%. The company continues to maintain a strong balance sheet with a cash surplus of Rs 4,158 Cr available for future acquisitions.
Confidence: HIGH
What changedThe company has finalized the specific dates for its previously proposed final dividend and its 79th Annual General Meeting.
Why it mattersThis is a routine distribution of profits to shareholders, reflecting the company's consistent payout policy despite a 35.6% decline in share price over the last 12 months.
Final Dividend: Rs 10 per shareRecord Date: August 7, 2026Dividend Yield: ~0.38%TTM EPS: Rs 85.11Cash Surplus: Rs 4,158 Cr
📅 Short termThe stock may trade ex-dividend a day or two prior to August 7, which typically results in a minor price adjustment equal to the dividend amount.
📈 Long termLimited structural significance; the focus remains on the company's ability to scale its Pharma CDMO and Biologicals segments to offset agrochemical volatility.
Key Highlights
Final dividend declared at Rs 10 per equity share for FY 2025-26
Record date for determining dividend eligibility is August 7, 2026
79th Annual General Meeting scheduled for August 14, 2026, via video conferencing
Dividend yield stands at approximately 0.38% against the current price of Rs 2,631.8
Company maintains a low Debt-to-Equity ratio of 0.01 with TTM PAT of Rs 1,291 Cr
👀 What to Watch
Investors interested in the dividend must hold the shares in their demat account by the record date of August 7, 2026. Monitor the AGM on August 14 for updates on the execution of the USD 1.4 billion order book.
PI Industries Converts Rs 1,000 Cr OFCDs into Equity in PI Health Sciences Subsidiary
PI Industries has exercised its option to convert Rs 10,000 million (Rs 1,000 crore) worth of Optionally Fully Convertible Debentures (OFCDs) into equity shares of its wholly-owned subsidiary, PI Health Sciences Limited (PIHS). The conversion results in the issuance of 72.46 crore equity shares at a fair value of Rs 13.80 per share. This internal restructuring does not involve any cash outflow or change in ownership, as PIHS remains a 100% subsidiary. The move is intended to strengthen the consolidated balance sheet and support the subsidiary's Pharma CRDMO business.
Key Highlights
Conversion of Rs 10,000 million (Rs 1,000 crore) OFCDs into equity shares of PI Health Sciences
Issuance of 72,46,37,687 equity shares at a fair value of Rs 13.80 per share
PI Health Sciences remains a 100% wholly-owned subsidiary with no change in control
Transaction involves no cash consideration or external share swap
Aims to strengthen the consolidated balance sheet and support the Pharma CRDMO segment
👀 What to Watch
This is a routine internal capital restructuring with no immediate impact on cash flows or valuation. Investors should focus on the operational growth of the Pharma CRDMO subsidiary as it scales its turnover.
PI Industries FY26 Revenue at ₹67,137 Mn; Pharma Grows 40% Amid AgChem Downcycle
PI Industries reported FY26 revenue of ₹67,137 million, maintaining a steady 25% EBITDA margin despite a challenging global agrochemical downcycle. The Pharma segment emerged as a high-growth engine with 40% annual growth, while Biologicals continued to compound at over 20%. The company maintains a robust debt-free balance sheet with ₹34,265 million in net cash. Management expects a recovery in exports by H2 FY27, supported by the launch of their first homegrown New Chemical Entity (NCE), Pioxaniliprole.
Key Highlights
FY26 consolidated revenue reached ₹67,137 million with a resilient EBITDA margin of 25%.
Pharma business delivered 40% growth in FY26, driven by strategic customer onboarding and CRDMO scaling.
Maintained a strong liquidity position with net cash of ₹34,265 million for future strategic investments.
New products now contribute 18% of total AgChem exports, highlighting successful portfolio de-risking.
First proprietary NCE, Pioxaniliprole, is set for market entry to transition the company toward an innovator model.
👀 What to Watch
Investors should monitor the commercial ramp-up of the new NCE and the recovery of export volumes in H2 FY27. The strong cash position provides significant optionality for M&A or further expansion into Life Sciences and Electronic Chemicals.
PI Industries Q4 FY26 Revenue Down 12% to ₹15,652 Mn; Final Dividend of ₹10 Declared
PI Industries reported a challenging Q4 FY26 with consolidated revenue declining 12% YoY to ₹15,652 Mn, primarily due to a 15% contraction in Agchem exports. EBITDA margins contracted to 22% from 26% a year ago, while PAT fell 39% to ₹2,002 Mn. Despite the cyclical downturn in the global agrochemical industry, the Pharma segment showed resilience with 40% annual growth in FY26. The company maintains a strong balance sheet with surplus cash of ₹34,265 Mn and has proposed a final dividend of ₹10 per share.
Key Highlights
Q4 Revenue fell 12% YoY to ₹15,652 Mn; FY26 Revenue declined 16% to ₹67,137 Mn.
EBITDA for Q4 dropped 26% YoY to ₹3,373 Mn with margins contracting by 402 bps to 22%.
Pharma segment revenue grew 40% YoY in FY26, now contributing ~6% of total exports.
Board recommended a final dividend of ₹10 per share, taking the total FY26 dividend to ₹15.
Maintained a robust cash position of ₹34,265 Mn despite a high FY26 capex of ₹11,508 Mn.
👀 What to Watch
Investors should monitor the recovery in global agrochemical demand and the scaling of the Pharma business, which is successfully diversifying the revenue mix. While cyclical headwinds persist, the company's strong cash reserves and innovation pipeline support long-term value compounding.
PI Industries FY26 Profit Drops 23% to ₹14,348 Million; Declares ₹10 Final Dividend
PI Industries reported a significant decline in its financial performance for the fiscal year ended March 31, 2026, with standalone revenue falling 18.3% to ₹61,827 million. Net profit followed suit, dropping from ₹18,665 million in FY25 to ₹14,348 million in FY26. Despite the earnings contraction, the board recommended a final dividend of ₹10 per share, bringing the total FY26 dividend to ₹15. The company also announced a major leadership transition, including the resignation of the Joint Managing Director and the appointment of a new Whole-time Director.
Key Highlights
Standalone Revenue from operations declined to ₹61,827 million in FY26 from ₹75,712 million in FY25.
Net Profit for the full year decreased by 23.1% YoY to ₹14,348 million.
Recommended a final dividend of ₹10 per share (1000%), totaling ₹15 for the full fiscal year.
Mr. Rajnish Sarna resigned as Joint Managing Director, transitioning to a Non-Executive role.
Dr. Atul Kumar Gupta appointed as Whole-time Director for a 3-year term effective May 19, 2026.
👀 What to Watch
Investors should exercise caution due to the sharp decline in annual revenue and profitability. Monitor management's guidance on recovery timelines and the impact of the significant leadership reshuffle on future operations.
PI Industries FY26 Profit Drops to ₹14,348 Million; Recommends ₹10 Final Dividend
PI Industries reported a significant decline in its financial performance for FY26, with standalone revenue falling to ₹61,827 million from ₹75,712 million in FY25. Net profit also contracted by approximately 23% to ₹14,348 million, leading to a drop in EPS from ₹123.03 to ₹94.57. Despite the lower earnings, the board has recommended a final dividend of ₹10 per share, bringing the total dividend for the year to ₹15. The company also announced a major management reshuffle, including the appointment of a new Whole-time Director and the transition of the Joint MD to a non-executive role.
Key Highlights
Standalone revenue for FY26 decreased by 18.3% YoY to ₹61,827 million.
Net profit for the full year declined to ₹14,348 million compared to ₹18,665 million in the previous year.
Recommended a final dividend of ₹10 per share (1000%), totaling ₹15 for the full fiscal year.
Significant management changes: Dr. Atul Kumar Gupta appointed as Whole-time Director; Mr. Rajnish Sarna resigned as Joint MD.
Standalone EPS for FY26 stood at ₹94.57, down from ₹123.03 in FY25.
👀 What to Watch
Investors should be cautious due to the double-digit decline in both revenue and profitability; wait for management commentary on the outlook for the agrochemical sector. The management reshuffle and dividend payout provide some stability, but the core business growth needs to be monitored closely.
PI Industries Declares ₹10 Final Dividend Amid Major Leadership Reshuffle and FY26 Results
PI Industries has announced a significant management transition, including the resignation of Mr. Rajnish Sarna as Joint Managing Director and the appointment of Dr. Atul Kumar Gupta as a Whole-time Director. For the financial year ended March 31, 2026, the company reported standalone revenue of ₹61,827 million, a decrease from ₹75,712 million in the previous year. Despite lower profits of ₹14,348 million compared to ₹18,665 million YoY, the board recommended a final dividend of ₹10 per share. This brings the total dividend for FY26 to ₹15 per share, representing a 1500% payout on the face value of ₹1.
Key Highlights
Recommended a final dividend of ₹10 per share, totaling ₹15 for the full financial year 2025-26.
Standalone FY26 revenue declined to ₹61,827 million from ₹75,712 million in FY25.
Mr. Rajnish Sarna resigned as Joint MD and transitioned to a Non-Executive Director role.
Dr. Atul Kumar Gupta appointed as Whole-time Director for a 3-year term effective May 19, 2026.
Dr. Marco Busch, Global Chief Scientific Officer, designated as Senior Management Personnel to lead R&D.
👀 What to Watch
Investors should closely monitor how the new leadership team addresses the year-on-year decline in revenue and profitability. While the dividend remains attractive, the transition in the Managing Director's office and the R&D leadership requires observation for strategic continuity.
PI Industries Recommends ₹10 Final Dividend; FY26 Total Dividend at ₹15 Per Share
PI Industries has recommended a final dividend of ₹10 per share for FY 2025-26, bringing the total annual payout to ₹15 per share. Despite the dividend, the company reported a significant decline in financial performance for Q4 FY26, with standalone revenue dropping to ₹13,914 million from ₹16,482 million YoY. Net profit for the quarter also saw a sharp decline to ₹1,978 million compared to ₹3,858 million in the previous year. Additionally, the company announced several leadership changes, including the resignation of the Joint Managing Director.
Key Highlights
Final dividend of ₹10 per share (1000%) recommended; total FY26 dividend stands at ₹15.
Standalone Q4 Revenue from operations fell 15.6% YoY to ₹13,914 million.
Standalone Q4 Net Profit declined significantly by 48.7% YoY to ₹1,978 million.
Full-year FY26 standalone PAT decreased to ₹14,348 million from ₹18,665 million in FY25.
Joint MD Rajnish Sarna resigned from his executive role, transitioning to a Non-Executive Director.
👀 What to Watch
Investors should exercise caution as the substantial year-on-year decline in both revenue and profit suggests operational headwinds. Monitor the upcoming AGM for management's guidance on recovery and the impact of leadership transitions.
PI Industries FY26 Revenue Drops 18% to ₹6,183 Cr; Declares ₹10 Final Dividend
PI Industries reported a challenging FY26 with standalone revenue from operations declining 18.3% YoY to ₹6,182.7 crore. Net profit for the full year fell by 23.1% to ₹1,434.8 crore, weighed down by an exceptional loss of ₹132.3 crore. Despite the earnings contraction, the board has recommended a final dividend of ₹10 per share, taking the total dividend for the year to ₹15. The company also announced a significant management reshuffle, including the resignation of the Joint Managing Director and the appointment of a new Whole-time Director.
Key Highlights
Standalone Revenue from operations fell 18.3% YoY to ₹6,182.7 crore for FY26.
Net Profit for the fiscal year decreased to ₹1,434.8 crore from ₹1,866.5 crore in FY25.
Recommended a final dividend of ₹10 per share (1000%), totaling ₹15 for the full year.
Reported an exceptional loss of ₹132.3 crore in FY26 compared to no such loss in the previous year.
Significant leadership changes including the resignation of Joint MD Rajnish Sarna and appointment of Dr. Atul Kumar Gupta as Whole-time Director.
👀 What to Watch
Investors should exercise caution as the company faces both top-line and bottom-line pressure alongside a major management transition. Monitor management commentary for the outlook on the agrochemical sector and the specific causes of the exceptional loss.
PI Industries Q3 FY26: Pharma Grows 50%, Gross Margins Expand to 59% Amid AgChem Headwinds
PI Industries reported Q3 FY26 revenue of INR 13,757 million, navigating a prolonged global AgChem down cycle and distributor destocking. While AgChem exports moderated, the Pharma segment delivered a robust 50% growth over the nine-month period. Gross margins expanded to 59% due to a favorable product mix and cost discipline, while EBITDA margins remained resilient at 27%. The company maintains a strong, debt-free balance sheet with net cash of INR 35 billion, supporting future strategic investments.
Key Highlights
Q3 FY26 revenue reached INR 13,757 million with gross margins expanding to 59%.
Pharma business segment delivered 50% year-on-year growth during the nine-month period.
Net cash position stands at INR 35 billion with a completely debt-free balance sheet.
Exceptional income of INR 1,260 million recorded from a pharma contingent consideration write-back.
Commercialized 5 new molecules in AgChem exports and 4 in the domestic market during the year.
👀 What to Watch
Investors should focus on the management's guidance of a recovery starting in Q4 FY26 and growth momentum in FY27. The strong cash reserves and expansion into Pharma and Biologicals provide a diversified growth cushion against AgChem cyclicality.
PI Industries Q3 FY26: Pharma Revenue Surges 50% Amid AgChem Headwinds; Net Cash at INR 35 Billion
PI Industries reported Q3 FY26 revenue of INR 13,757 million, impacted by global AgChem destocking and soft commodity prices. Despite these headwinds, the Pharma segment delivered a robust 50% year-on-year growth for the nine-month period, and gross margins expanded to 59%. The company maintains a strong, debt-free balance sheet with net cash of INR 35 billion. Management expects sequential volume improvement starting Q4 FY26 and a return to growth momentum in FY27.
Key Highlights
Pharma segment revenue grew 50% YoY over the 9-month period, driven by new strategic accounts and big pharma customers.
Gross margins expanded to 59% in Q3 FY26, supported by a favorable product mix and cost discipline.
Maintains a robust debt-free balance sheet with net cash of INR 35 billion available for strategic investments.
Commercialized 5 new molecules in AgChem exports and 4 in domestic agri-science during the period.
Exceptional income of INR 1,260 million recorded due to a write-back of contingent consideration in the pharma business.
👀 What to Watch
Investors should monitor the guided recovery in AgChem volumes in Q4 FY26 and the continued scaling of the high-margin Pharma and Biologicals platforms. The strong cash position and new product pipeline offer long-term resilience despite current industry-wide cyclical pressures.
PI Industries Q3 FY26: Revenue Drops 28% YoY Amid Export Phasing; Pharma Grows 50% in 9M
PI Industries reported a weak Q3 FY26 with consolidated revenue declining 28% YoY to ₹13,757 million, primarily driven by a 32% drop in Agchem exports due to customer delivery phasing. EBITDA margins contracted by 495 bps to 22%, although gross margins improved significantly by 631 bps to 59% due to a favorable product mix. The Pharma segment remains a bright spot, posting 50% YoY growth for 9M FY26. The company maintains a strong, debt-free balance sheet with a cash surplus of ₹35,066 million and declared an interim dividend of ₹5.00 per share.
Key Highlights
Q3 FY26 Revenue fell 28% YoY to ₹13,757 Mn, while EBITDA declined 41% to ₹3,027 Mn.
Agchem Exports volume decreased 29% in Q3, impacted by delivery schedules and high base effects.
Pharma vertical revenue grew 50% YoY in 9M FY26 to ₹1,957 Mn, now contributing ~5% of exports.
Net Profit of ₹3,113 Mn includes an exceptional writeback of ₹1,260 Mn in contingent consideration.
9M FY26 Capex stood at ₹7,225 Mn, focusing on manufacturing and R&D infrastructure.
👀 What to Watch
Investors should watch for a volume recovery in Q4 as management indicates the Q3 decline was largely due to timing and delivery phasing. The rapid growth in the Pharma and Biologicals segments offers long-term diversification, but near-term stock performance may be pressured by the core Agchem slowdown.
PI Industries Declares Rs 5 Interim Dividend; Sets Feb 23, 2026 as Record Date
PI Industries has declared an interim dividend of Rs 5 per equity share (500% of face value) for the financial year 2025-26. The company has fixed February 23, 2026, as the record date to determine eligible shareholders for this payout. Investors are required to submit tax-related documents by February 21, 2026, to ensure appropriate TDS rates are applied. Notably, the company will now process all dividend payments exclusively through electronic modes as per SEBI regulations.
Key Highlights
Interim dividend of Rs 5 per equity share of face value Re 1 declared for FY 2025-26
Record date for determining shareholder eligibility is fixed as February 23, 2026
Standard TDS of 10% for resident shareholders with PAN; 20% for those without valid PAN/Aadhaar link
TDS exemption available for resident individuals if total dividend for FY 2025-26 does not exceed Rs 10,000
Deadline for submission of tax exemption forms (15G/15H) and other documents is February 21, 2026
👀 What to Watch
Shareholders should ensure their bank account and KYC details are updated with their Depository Participant or RTA to receive the dividend electronically. Eligible investors should submit Form 15G/15H by February 21 to avoid higher tax deductions.
PI Industries Declares ₹5 Interim Dividend; Q3 Consolidated Revenue Falls 27.6% YoY
PI Industries reported a significant decline in consolidated revenue for Q3 FY26, falling to ₹13,757 million from ₹19,008 million in the previous year. Consolidated net profit also decreased to ₹3,113 million compared to ₹3,727 million YoY, despite a net exceptional gain of ₹1,051 million. To reward shareholders, the board declared an interim dividend of ₹5 per share (500% of face value) with a record date of February 23, 2026. The company also recognized a ₹206 million exceptional charge on a standalone basis due to the implementation of New Labour Codes.
Key Highlights
Consolidated revenue from operations declined 27.6% YoY to ₹13,757 million.
Consolidated PAT for the quarter stood at ₹3,113 million, down 16.5% from ₹3,727 million YoY.
Interim dividend of ₹5 per equity share (500%) declared with a record date of Feb 23, 2026.
Exceptional gain of ₹1,051 million reported in consolidated results for the quarter.
Basic EPS decreased to ₹20.52 from ₹24.55 in the corresponding quarter of the previous year.
👀 What to Watch
Investors should exercise caution as the sharp decline in top-line growth and margins indicates headwinds in the agrochemical sector. While the ₹5 dividend provides some immediate yield, the focus should remain on management's outlook for demand recovery.
PI Industries Declares ₹5 Interim Dividend Amidst Sharp Decline in Q3 Revenue
PI Industries has declared an interim dividend of ₹5 per equity share (500% of face value) for FY26, with the record date set for February 23, 2026. The company's consolidated revenue for Q3 FY26 saw a significant decline to ₹13,757 million from ₹19,008 million in the same period last year. Consolidated net profit stood at ₹3,113 million, which was bolstered by a one-time exceptional gain of ₹1,051 million. Standalone performance was notably weaker, with revenue falling nearly 29% YoY to ₹12,696 million.
Key Highlights
Interim dividend of ₹5 per share declared with a record date of February 23, 2026.
Consolidated revenue from operations fell 27.6% YoY to ₹13,757 million in Q3 FY26.
Consolidated PAT decreased to ₹3,113 million from ₹3,727 million in the previous year's quarter.
Standalone PAT dropped significantly to ₹2,816 million compared to ₹4,238 million YoY.
An exceptional gain of ₹1,051 million was recorded at the consolidated level, offsetting operational weakness.
👀 What to Watch
The sharp contraction in both revenue and standalone profits indicates significant operational headwinds in the agrochemical segment. Investors should focus on the sustainability of margins and management's outlook on demand recovery before making new entries.
PI Industries Q3 Net Profit Falls 16.5% to ₹311 Cr; Declares ₹5 Interim Dividend
PI Industries reported a weak set of numbers for Q3 FY26, with consolidated revenue from operations declining 27.6% YoY to ₹13,757 million. Consolidated net profit for the quarter fell 16.5% to ₹3,113 million, even after accounting for a net exceptional gain of ₹1,051 million. The company declared an interim dividend of ₹5 per share (500% of face value) with a record date of February 23, 2026. Standalone performance mirrored the consolidated trend, with revenue dropping nearly 29% YoY, reflecting significant headwinds in the agrochemical sector.
Key Highlights
Consolidated Revenue from operations dropped 27.6% YoY to ₹13,757 million from ₹19,008 million in the previous year.
Consolidated Net Profit decreased by 16.5% YoY to ₹3,113 million, supported by an exceptional gain of ₹1,051 million.
Declared an interim dividend of ₹5 per equity share for FY 2025-26, payable by March 13, 2026.
Standalone results included an exceptional loss of ₹206 million due to the implementation of New Labour Codes.
The company confirmed that the entire ₹20,000 million raised through QIP in 2020 has now been fully utilized.
👀 What to Watch
The significant decline in both top-line and bottom-line performance suggests a challenging environment for the company's core agrochemical business. Investors should exercise caution and wait for management commentary on demand recovery and the nature of the consolidated exceptional gain before making new entries.
